EFFECT OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN ON BODY WEIGHT, LIPID PROFILE AND BLOOD PRESSURE IN TYPE 2 DIABETICS

Authors

  • Mazhar Hussain Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, Pakistan
  • Habib ur Rehman Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, Pakistan
  • Abdul Qudoos Arain Department of Pharmacology, HBS Medical & Dental College, Islamabad, Pakistan.
  • Amanat Ali Department of Pharmacology, HBS Medical & Dental College, Islamabad, Pakistan
  • Sameer Ahmed Department of Pharmacology, HBS Medical & Dental College, Islamabad, Pakistan
  • Mehwish Tayyab Department of Pharmacology, HBS Medical & Dental College, Islamabad, Pakistan

DOI:

https://doi.org/10.69656/pjp.v20i2.1607

Keywords:

Dapagliflozin, Empagliflozin, BMI, HbA1c, Lipid Profile, Blood Pressure

Abstract

Background: Cardiovascular disease (CVD) is a leading cause of death in type 2 diabetes mellitus (T2DM) patients with risk factors including weight, lipid profile, and blood pressure. Evidence suggests sodium-glucose co-transporter 2 (SGLT-2) inhibitors benefit T2DM patients. This study investigated the effects of SGLT-2 inhibitors on these risk factors in T2DM patients. Methods: This quasi-experimental study at Sheikh Zayed Medical College/Hospital, Rahim Yar Khan randomized T2DM patients with inadequate glycaemic control. First group received dapagliflozin 5?10 mg and second group received empagliflozin 10-25 mg as add-on therapy to conventional antidiabetic drugs for 12 weeks. The dose was adjusted based on serum blood sugar, with primary endpoints assessing changes in glycaemic control (blood sugar and HbA1c) from baseline. Secondary endpoints included recording additional glycaemic effects (body weight, BMI, lipid profile, and blood pressure) from baseline to endpoint. Results: Both drugs showed excellent tolerability and safety profiles with no major adverse effects. Significant reductions in body weight (empagliflozin 86.7±18 to 78±16.5 Kg, p=0.001; dapagliflozin 89.8±12 to 83±10 Kg, p=0.005), and BMI (empagliflozin 28±5.5 to 26.5±4.2 Kg/m², p=0.003; dapagliflozin 29.6±4.2 to 25.7±5.8 Kg/m², p=0.002) were observed. Both drugs significantly improved glycaemic control, fasting blood sugar (empagliflozin 180±32 to 140±44 mg/dL, p=0.003; dapagliflozin 190±48 to 150±33 mg/dL, p=0.005) and HbA1c (empagliflozin 9.7±2.6 to 7.5±1.8%, p=0.004; dapagliflozin 9.0±1.82 to 7.0±2.2%, p=0.001). Neither drug showed significant improvements in blood pressure or serum lipid profile. Conclusion: Empagliflozin and dapagliflozin have a modest effect on CVD risk factors in T2DM patients.

Pak J Physiol 2024;20(2):36-40

Downloads

Download data is not yet available.

References

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Prac 2019;157:107843.

Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol 2018;34(5):575–84.

Fernandes SL, Vangipurapu J, Laakso M. The “Common Soil Hypothesis” revisited –risk factors for type 2 diabetes and cardiovascular disease. Metabolites 2021;11(10):691.

Plodkowski RA, McGarvey ME, Huribal HM, Reisinger-Kindle K, Kramer B, Solomon M, et al. SGLT2 inhibitors for type 2 diabetes mellitus treatment. Federal Pract 2015;32(Suppl 11):8–15S.

Wilcox T, De Block C, Schwartzbard AZ, Newman JD. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol 2020;75(16):1956–74.

Hsia DS, Grove O, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017;24(1):73–9.

Ahmadieh H, Azar S. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus. Diabetes Technol Ther 2017;19(9):507–12.

Giugliano D, Esposito K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc Diabetol 2019;18(1):94.

Rao S. Use of sodium-glucose cotransporter-2 inhibitors in clinical practice for heart failure prevention and treatment: beyond type 2 diabetes. A narrative review. Adv Ther 2022;39(2):845–61.

Eickhoff MK, Olsen FJ, Frimodt-Møller M, Diaz LJ, Faber J, Jensen MT, et al. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria –A double blind randomized placebo-controlled crossover trial. J Diabetes Complications 2020;34(7):107590.

Mirabelli M, Chiefari E, Caroleo P, Vero R, Brunetti FS, Corigliano DM, et al. Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus. J Diabetes Res 2019;2019:3971060.

Jiang Y, Yang P, Fu L, Sun L, Shen W, Wu Q. Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. Front Endocrinol 2022;13:802992.

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 2021;27(11):1954–60.

Bruno L, Vincent D, Luc D, Xavier A, Jehan-Michel B, Pierre-Henri B, et al. Outpatient healthcare and clinical trials in the care pathway: Organisational and regulatory aspects and tools Therapies 2022;77(1):37–48.

Ptaszynska A, Johnsson KM, Parikh SJ, De Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf 2014;37:815–29.

Nath RK, Pandit N, Raj A, Pandit BN, Kumar V, Bhardwaj R, et al. Cardiovascular outcomes of antidiabetic drugs. Asian J Med Sci 2021;12(3):98–106.

Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2016;13(2):119–26.

Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E, Yajima T. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16?week double?blind treatment period. J Diabetes Investig 2016;7(4):55–64.

Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract 2019;151:65–73.

Syed SH, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, et al. A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem 2105;13(2):105–12.

Schubert A, Buchholt AT, El Khoury AC, Kamal A, Taieb V. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Curr Med Res Opin 2017;33(6):1155–63.

Lee PCH, Gu Y, Yeung MY, Fong CHY, Woo YC, Chow WS, et al. Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther 2018;9(1):285–95.

Simental-Mendia M, Sanchez-Garcia A, Rodriguez-Ramirez M, Simental-Mendia LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2021;163:105319.

Muzurovi? E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother 2020;21(17):2125–35.

Hong JY, Park KY, Kim JD, Hwang WM, Lim DM. Effects of 6 months of dapagliflozin treatment on metabolic profile and endothelial cell dysfunction for obese type 2 diabetes mellitus patients without atherosclerotic cardiovascular disease. J Obes Metab Syndr 2020;29(3):215–21.

Zhao D, Liu H, Dong P. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens 2019;33(4):327–39.

Yanai H, Hakoshima M, Adachi H, Kawaguchi A, Waragai Y, Harigae T, et al. Effects of six kinds of sodium-glucose cotransporter 2 inhibitors on metabolic parameters, and summarized effect and its correlations with baseline data. J Clin Med Res 2017;9(7):605–12.

Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Sako A, et al. Effects of sodium-glucose cotransporter 2 inhibitors on metabolic parameters in patients with type 2 diabetes: a chart-based analysis. J Clin Med Res 2016;8(3):237–43.

Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: A systematic review and meta?analysis of randomized?controlled trials. J Am Heart Assoc 2021;10:e019463.

Downloads

Published

30-06-2024

How to Cite

1.
Hussain M, Habib ur Rehman, Arain AQ, Amanat Ali, Sameer Ahmed, Mehwish Tayyab. EFFECT OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN ON BODY WEIGHT, LIPID PROFILE AND BLOOD PRESSURE IN TYPE 2 DIABETICS. Pak J Phsyiol [Internet]. 2024 Jun. 30 [cited 2024 Jul. 20];20(2):36-40. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/1607